Terms: = Prostate cancer AND RHOA, ENSG00000067560, 387, ARHA, RhoA, RHOH12, RHO12, ARH12, Rho12 AND Diagnosis
27 results:
1. Assessment of the Surgical Oncology Case Volume Within the Public Sector in Tanzania.
Brand NR; Akoko L; Kotecha V; Mwakyembe T; Mwashambwa M; Hamid R; Hando D; Komba C; Mwanga A; Mbele P; Itule P; Jackson J; Misidai M; Gaskill C; Ozgediz D
JCO Glob Oncol; 2024 Mar; 10():e2300316. PubMed ID: 38452305
[TBL] [Abstract] [Full Text] [Related]
2. Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive prostate cancer.
Mitchell AP; Nemirovsky D; Mishra Meza A; Chakraborty N; Persaud S; Farooki A; Morris MJ
JCO Oncol Pract; 2024 Mar; 20(3):393-400. PubMed ID: 38190588
[TBL] [Abstract] [Full Text] [Related]
3. Variations in Age-Adjusted prostate cancer Incidence Rates by Race and Ethnicity After Changes in prostate-Specific Antigen Screening Recommendation.
Lai SM; Keighley J; Garimella S; Enko M; Parker WP
JAMA Netw Open; 2022 Nov; 5(11):e2240657. PubMed ID: 36342715
[TBL] [Abstract] [Full Text] [Related]
4. Overview of seminal fluid biomarkers for the evaluation of chronic prostatitis: a scoping review.
Moryousef J; Blankstein U; Curtis Nickel J; Krakowsky Y; Gilron I; Jarvi K
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):627-640. PubMed ID: 34845305
[TBL] [Abstract] [Full Text] [Related]
5. The Comparison of Imaging and Clinical Methods to Estimate prostate Volume: A Single-Centre Retrospective Study.
Massanova M; Robertson S; Barone B; Dutto L; Caputo VF; Bhatt JR; Ahmad I; Bada M; Obeidallah A; Crocetto F
Urol Int; 2021; 105(9-10):804-810. PubMed ID: 34247169
[TBL] [Abstract] [Full Text] [Related]
6. Pharmacokinetic modeling of dynamic contrast-enhanced (DCE)-MRI in PI-RADS category 3 peripheral zone lesions: preliminary study evaluating DCE-MRI as an imaging biomarker for detection of clinically significant prostate cancers.
Abreu-Gomez J; Lim C; Cron GO; Krishna S; Sadoughi N; Schieda N
Abdom Radiol (NY); 2021 Sep; 46(9):4370-4380. PubMed ID: 33818626
[TBL] [Abstract] [Full Text] [Related]
7. Men's sexual help-seeking and care needs after radical prostatectomy or other non-hormonal, active prostate cancer treatments.
Hyde MK; Opozda M; Laurie K; Vincent AD; Oliffe JL; Nelson CJ; Dunn J; Chung E; Gillman M; Manecksha RP; Wittert G; Chambers SK
Support Care Cancer; 2021 May; 29(5):2699-2711. PubMed ID: 32978635
[TBL] [Abstract] [Full Text] [Related]
8. The Risk of Second Primary Malignancies in Patients With Lung Neuroendocrine Tumors: A Population-Based Study on SEER Database.
Bu X; Wang X; Wei L; Liu J; Chen M
Curr Probl Cancer; 2020 Dec; 44(6):100613. PubMed ID: 32563531
[TBL] [Abstract] [Full Text] [Related]
9. The Identification of Key Gene Expression Signature in prostate cancer.
Huang Y; Cao Q; Song Z; Ruan H; Wang K; Chen K; Zhang X
Crit Rev Eukaryot Gene Expr; 2020; 30(2):153-168. PubMed ID: 32558494
[TBL] [Abstract] [Full Text] [Related]
10. What is the impact of rerouting a cancer diagnosis from emergency presentation to GP referral on resource use and survival? Evidence from a population-based study.
Laudicella M; Walsh B; Burns E; Li Donni P; Smith PC
BMC Cancer; 2018 Apr; 18(1):394. PubMed ID: 29625606
[TBL] [Abstract] [Full Text] [Related]
11. Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study.
Pompe RS; Smith A; Bandini M; Marchioni M; Martel T; Preisser F; Leyh-Bannurah SR; Schiffmann J; Saad F; Huland H; Graefen M; Shariat SF; Tilki D; Karakiewicz PI
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):71-77. PubMed ID: 29339806
[TBL] [Abstract] [Full Text] [Related]
12. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL
Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815
[TBL] [Abstract] [Full Text] [Related]
13. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia.
Gordon LG; James R; Tuffaha HW; Lowe A; Yaxley J
J Magn Reson Imaging; 2017 May; 45(5):1304-1315. PubMed ID: 27726240
[TBL] [Abstract] [Full Text] [Related]
14. Diagnostic Importance of Selected Protein Serum Markers in the Primary Diagnostics of prostate cancer.
Čapoun O; Soukup V; Kalousová M; Sobotka R; Pešl M; Zima T; Hanuš T
Urol Int; 2015; 95(4):429-35. PubMed ID: 26159681
[TBL] [Abstract] [Full Text] [Related]
15. Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the prostate cancer Registry.
Evans SM; Millar JL; Frydenberg M; Murphy DG; Davis ID; Spelman T; Bolton DM; Giles GG; Dean J; Costello AJ; Frauman AG; Kearns PA; Day L; Daniels C; McNeill JJ
BJU Int; 2014 Nov; 114(5):680-90. PubMed ID: 24128010
[TBL] [Abstract] [Full Text] [Related]
16. cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study.
Jess T; Horváth-Puhó E; Fallingborg J; Rasmussen HH; Jacobsen BA
Am J Gastroenterol; 2013 Dec; 108(12):1869-76. PubMed ID: 23978954
[TBL] [Abstract] [Full Text] [Related]
17. Unbiased estimates of long-term net survival of solid cancers in France.
Jooste V; Grosclaude P; Remontet L; Launoy G; Baldi I; Molinié F; Arveux P; Bossard N; Bouvier AM; Colonna M;
Int J Cancer; 2013 May; 132(10):2370-7. PubMed ID: 23001495
[TBL] [Abstract] [Full Text] [Related]
18. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer.
Davidsson S; Fiorentino M; Andrén O; Fang F; Mucci LA; Varenhorst E; Fall K; Rider JR
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2280-7. PubMed ID: 21953116
[TBL] [Abstract] [Full Text] [Related]
19. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials.
Djulbegovic M; Beyth RJ; Neuberger MM; Stoffs TL; Vieweg J; Djulbegovic B; Dahm P
BMJ; 2010 Sep; 341():c4543. PubMed ID: 20843937
[TBL] [Abstract] [Full Text] [Related]
20. [Literature-mining and bioinformatic analysis of androgen-independent prostate cancer-specific genes].
Li TQ; Feng CQ; Zou YG; Shi R; Liang S; Mao XM
Zhonghua Nan Ke Xue; 2009 Dec; 15(12):1102-7. PubMed ID: 20180422
[TBL] [Abstract] [Full Text] [Related]
[Next]
